Muscle relaxant mechanism

"Muscle relaxant mechanism" is a **general phrase** referring to the diverse ways drugs called muscle relaxants reduce muscle tone, induce paralysis, or relieve spasms. Muscle relaxants primarily fall into two pharmacological groups: **neuromuscular blocking agents (e.g., agents targeting nicotinic acetylcholine receptors at the neuromuscular junction such as succinylcholine, rocuronium)** and **centrally acting spasmolytics (such as baclofen or benzodiazepines, acting through central nervous system targets)**[3][7][6][2][1][5]. Mechanistically, neuromuscular blockers are further subdivided into depolarizing agents (nicotinic receptor agonists, causing persistent depolarization and paralysis) and non-depolarizing agents (competitive antagonists at the acetylcholine receptor preventing depolarization)[7][1][6][4]. The phrase "muscle relaxant mechanism" is *not a specific protein, receptor, enzyme, or gene* and thus does not correspond to a molecular target entry. For structured drug-target information, the analysis must instead focus on concrete molecular entities such as the **nicotinic acetylcholine receptor (nAChR)** at the neuromuscular junction (for neuromuscular blockers) or the **GABA-A receptor** (for benzodiazepines), **GABA-B receptor** (for baclofen), or **ryanodine receptor type 1** (for dantrolene)[5][7]. **In summary:** - The submitted name is a mechanistic category, not a canonical molecular target, and cannot be structured as required. For accurate drug-target mapping, substitute the general mechanism with a specific molecular target, such as "Nicotinic acetylcholine receptor (muscle type)" for neuromuscular blockers or "GABA-A receptor" for benzodiazepines.

Other names

Muscle relaxant actionMuscle relaxant pharmacodynamicsSkeletal muscle relaxation mechanism